Key Drivers
- Solid liquidity
- Q4 EBITDA rebound
- High intangibles
AIAI Summary
Avanos is no longer a growth story but a cash-flow recovery play where successful execution of a China exit and realization of $15–$20M in annualized savings (plus tariff mitigation) are the primary drivers of margin expansion and valuation re-rating. The key risk/opportunity is binary and execution-driven: if management delivers the supply‑chain move and cost saves by mid‑2026, EBITDA and FCF will meaningfully improve; if not, tariffs, higher CapEx, and elevated SG&A will keep the stock depressed.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Solid liquidity
- •Q4 EBITDA rebound
- •High intangibles
AVNS is liquid and cash-generating with a meaningful Q4 operating rebound, but full‑year operating losses, large intangibles and high SG&A keep profitability pressured.
Price Behavior
Key Price Behavior Insights:
- •Downward momentum
- •Defended support
- •Failed rallies
Over the last month AVNS has been in a clear short-term downtrend—closing $13.05 on 2026-03-20 (~15.6% below the 02-20 high of $15.46) and sitting below the ~$13.83 last-month SMA, with near-term support around $13.0–$13.4 and resistance near $15.2–$15.5. #short-term
~15.6% decline from $15.46 (02-20) to $13.05 (03-20) signaling sustained selling pressure
Sentiment & News
Key News Insights:
- •Operational beat
- •Cost-savings plan
- •Governance probe
Avanos beat Q4/FY25 expectations with organic growth and a $15–$20M cost-savings plan while pursuing M&A, but shares plunged amid margin/tariff worries, board changes and a shareholder probe.
Operational outperformance and planned efficiencies bolster medium-term outlook, but margin headwinds, tariffs and shareholder scrutiny increase near-term share volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings